Professor Mark Cooper

Professor
Medicine, Concord Clinical School


Map

Biographical details

Professor Mark S Cooper is Head of the Discipline of Medicine at Concord Hospital and Head of the Adrenal Steroid Lab at the ANZAC Research Institute. He was previously a Senior Clinical Lecturer and Consultant in Endocrinology and General Medicine at the University of Birmingham, UK.

Research interests

Adrenal steroid metabolism, 11beta hydroxysteroid dehydrogenases, steroid hormone action, basic and clinical bone research.

International links

United Kingdom

(University of Birmingham) Honorary Senior Research Fellow. Ongoing PhD student and post-doctoral research fellow supervision. Ongoing clinical trials.

Selected grants

2014

  • EVOS® FL Auto cell imaging system; Nicholson G, Clark G, Zhou H, Jessup W, Le Couteur D, McMahon A, McLachlan A, Allan C, Handelsman D, Hart D, Walters K, Kritharides L, Kockx M, Kennerson M, Cooper M, Seibel M, Verma N, Silveira P, Fromm P, Simanainen U, Cogger V, Zheng Y; National Health and Medical Research Council (NHMRC)/Equipment Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gathercole, L., Lavery, G., Morgan, S., Cooper, M., Sinclair, A., Tomlinson, J., Stewart, P. (2013). 11β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 34(4), 525-555. [More Information]
  • Crabtree, N., Hogler, W., Cooper, M., Shaw, N. (2013). Diagnostic evaluation of bone densitometric size adjustment techniques in children with and without low trauma fractures. Osteoporosis International, 24(7), 2015-2024. [More Information]
  • Seibel, M., Cooper, M., Zhou, H. (2013). Glucocorticoid-induced osteoporosis: Mechanisms, management, and future perspectives. The Lancet Diabetes & Endocrinology, 1(1), 59-70. [More Information]
  • Cooper, M., Thickett, D., Stewart, P. (2013). Reduced cortisol metabolism during critical illness. The New England Journal of Medicine, 369(5), 480-480. [More Information]
  • Hardy, R., Seibel, M., Cooper, M. (2013). Targeting 11beta-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease. Current opinion in pharmacology, 13(3), 440-444. [More Information]
  • Parekh, D., Dancer, R., Lax, S., Cooper, M., Martineau, A., Fraser, W., Tucker, O., Alderson, D., Perkins, G., Gao-Smith, F., et al (2013). Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials, 14(100), 1-7. [More Information]
  • Cooper, M., Zhou, H., Seibel, M. (2012). Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets? Journal of Bone and Mineral Research, 27(11), 2238-2241. [More Information]
  • Cooper, M., Stewart, P., Kriel, H., Sayers, A., Fraser, W., Williams, A., Probert, C., Tobias, J., Stewart, P., Cornely, O. (2011). Can 11β-hydroxysteroid dehydrogenase activity predict the sensitivity of bone to therapeutic glucocorticoids in inflammatory bowel disease? Calcified Tissue International, 89(3), 246-251. [More Information]
  • Cooper, M., Cooper, M. (2011). Disorders of calcium metabolism and parathyroid disease. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(6), 975-983. [More Information]
  • Cooper, M., Venkatesh, B., Cordina, R. (2011). Endocrine management in the intensive care unit. Preface. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(5), 703-704. [More Information]
  • Cooper, M., Hardy, R., Trotter, M. (2011). Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells? Frontiers in Endocrinology, 2, 24-24. [More Information]
  • Cooper, M., Hassan-Smith, Z., Cooper, W. (2011). Overview of the endocrine response to critical illness: how to measure it and when to treat. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(5), 705-717. [More Information]
  • Cooper, M., Hidalgo, E., Essex, S., Yeo, L., Curnow, S., Filer, A., Thomas, A., McGettrick, H., Salmon, M., Buckley, C., et al (2011). The response of T cells to interleukin-6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue. Arthritis & Rheumatism, 63(11), 3284-3293. [More Information]
  • Cooper, M., Hardy, R., Crabtree, N. (2010). Adrenal gland and bone. Archives of Biochemistry and Biophysics, 503(1), 137-145. [More Information]
  • Cooper, M., Craik, R. (2010). Glucocorticoid-induced osteoporosis: how best to avoid fractures. Therapeutic Advances in Chronic Diseases, 1(1), 17-23. [More Information]
  • Cooper, M., Crabtree, N., Bebbington, N., Chapman, D., Wahid, Y., Ayuk, J., Boivin, C., Gittoes, N., National Osteoporosis Guidelines Group, N., Cox, N. (2010). Impact of UK National Guidelines based on FRAX®--comparison with current clinical practice. Clinical Endocrinology, 73(4), 452-456. [More Information]
  • Cooper, M., Ayuk, J., Gittoes, N., Costa-Pereira, A. (2010). New perspectives in the management of primary hyperparathyroidism. Therapeutic Advances in Endocrinology and Metabolism, 1(5), 197-205. [More Information]
  • Cooper, M., Gittoes, N., Craig, G. (2010). Primary hyperparathyroidism--is mild disease worth treating? Clinical Medicine, 10(1), 45-49. [More Information]
  • Stewart, P., Cooper, M., Kaur, K., Hardy, R., Ahasan, M., Eijken, M., van Leeuwen, J., Filer, A., Thomas, A., Raza, K., et al (2010). Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Annals of the Rheumatic Diseases, 69(6), 1185-1190. [More Information]
  • Cooper, M., Raza, K., Hardy, R., Costa-Pereira, A. (2010). The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology, 49(11), 2016-2023. [More Information]
  • Cooper, M., Costa, L. (2010). Thyroid gland: Variation in 'normal' thyroid function--effect on bone health? Nature Reviews Endocrinology, 6(11), 599-600. [More Information]
  • Cooper, M., Stewart, P., Stewart, P., Cunha, F. (2009). 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Journal of Clinical Endocrinology and Metabolism, 94(12), 4645-4654. [More Information]
  • Cooper, M., Hardy, R., Curnow, S. (2009). Bone loss in inflammatory disorders. The Journal of Endocrinology, 201(3), 309-320. [More Information]

2013

  • Gathercole, L., Lavery, G., Morgan, S., Cooper, M., Sinclair, A., Tomlinson, J., Stewart, P. (2013). 11β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 34(4), 525-555. [More Information]
  • Crabtree, N., Hogler, W., Cooper, M., Shaw, N. (2013). Diagnostic evaluation of bone densitometric size adjustment techniques in children with and without low trauma fractures. Osteoporosis International, 24(7), 2015-2024. [More Information]
  • Seibel, M., Cooper, M., Zhou, H. (2013). Glucocorticoid-induced osteoporosis: Mechanisms, management, and future perspectives. The Lancet Diabetes & Endocrinology, 1(1), 59-70. [More Information]
  • Cooper, M., Thickett, D., Stewart, P. (2013). Reduced cortisol metabolism during critical illness. The New England Journal of Medicine, 369(5), 480-480. [More Information]
  • Hardy, R., Seibel, M., Cooper, M. (2013). Targeting 11beta-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease. Current opinion in pharmacology, 13(3), 440-444. [More Information]
  • Parekh, D., Dancer, R., Lax, S., Cooper, M., Martineau, A., Fraser, W., Tucker, O., Alderson, D., Perkins, G., Gao-Smith, F., et al (2013). Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials, 14(100), 1-7. [More Information]

2012

  • Cooper, M., Zhou, H., Seibel, M. (2012). Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets? Journal of Bone and Mineral Research, 27(11), 2238-2241. [More Information]

2011

  • Cooper, M., Stewart, P., Kriel, H., Sayers, A., Fraser, W., Williams, A., Probert, C., Tobias, J., Stewart, P., Cornely, O. (2011). Can 11β-hydroxysteroid dehydrogenase activity predict the sensitivity of bone to therapeutic glucocorticoids in inflammatory bowel disease? Calcified Tissue International, 89(3), 246-251. [More Information]
  • Cooper, M., Cooper, M. (2011). Disorders of calcium metabolism and parathyroid disease. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(6), 975-983. [More Information]
  • Cooper, M., Venkatesh, B., Cordina, R. (2011). Endocrine management in the intensive care unit. Preface. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(5), 703-704. [More Information]
  • Cooper, M., Hardy, R., Trotter, M. (2011). Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells? Frontiers in Endocrinology, 2, 24-24. [More Information]
  • Cooper, M., Hassan-Smith, Z., Cooper, W. (2011). Overview of the endocrine response to critical illness: how to measure it and when to treat. Best Practice and Research: Clinical Endocrinology and Metabolism, 25(5), 705-717. [More Information]
  • Cooper, M., Hidalgo, E., Essex, S., Yeo, L., Curnow, S., Filer, A., Thomas, A., McGettrick, H., Salmon, M., Buckley, C., et al (2011). The response of T cells to interleukin-6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue. Arthritis & Rheumatism, 63(11), 3284-3293. [More Information]

2010

  • Cooper, M., Hardy, R., Crabtree, N. (2010). Adrenal gland and bone. Archives of Biochemistry and Biophysics, 503(1), 137-145. [More Information]
  • Cooper, M., Craik, R. (2010). Glucocorticoid-induced osteoporosis: how best to avoid fractures. Therapeutic Advances in Chronic Diseases, 1(1), 17-23. [More Information]
  • Cooper, M., Crabtree, N., Bebbington, N., Chapman, D., Wahid, Y., Ayuk, J., Boivin, C., Gittoes, N., National Osteoporosis Guidelines Group, N., Cox, N. (2010). Impact of UK National Guidelines based on FRAX®--comparison with current clinical practice. Clinical Endocrinology, 73(4), 452-456. [More Information]
  • Cooper, M., Ayuk, J., Gittoes, N., Costa-Pereira, A. (2010). New perspectives in the management of primary hyperparathyroidism. Therapeutic Advances in Endocrinology and Metabolism, 1(5), 197-205. [More Information]
  • Cooper, M., Gittoes, N., Craig, G. (2010). Primary hyperparathyroidism--is mild disease worth treating? Clinical Medicine, 10(1), 45-49. [More Information]
  • Stewart, P., Cooper, M., Kaur, K., Hardy, R., Ahasan, M., Eijken, M., van Leeuwen, J., Filer, A., Thomas, A., Raza, K., et al (2010). Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Annals of the Rheumatic Diseases, 69(6), 1185-1190. [More Information]
  • Cooper, M., Raza, K., Hardy, R., Costa-Pereira, A. (2010). The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology, 49(11), 2016-2023. [More Information]
  • Cooper, M., Costa, L. (2010). Thyroid gland: Variation in 'normal' thyroid function--effect on bone health? Nature Reviews Endocrinology, 6(11), 599-600. [More Information]

2009

  • Cooper, M., Stewart, P., Stewart, P., Cunha, F. (2009). 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Journal of Clinical Endocrinology and Metabolism, 94(12), 4645-4654. [More Information]
  • Cooper, M., Hardy, R., Curnow, S. (2009). Bone loss in inflammatory disorders. The Journal of Endocrinology, 201(3), 309-320. [More Information]

To update your profile click here. For support on your academic profile contact .